Spiral Therapeutics Receives Positive IND Submission Guidance from FDA

Spiral Therapeutics Receives Positive IND Submission Guidance from FDA
  • September 30, 2017
  • News

Spiral Therapeutics, Inc., a biopharmaceutical company developing first-in-class therapies targeting inner ear disorders, reported positive feedback from the US Food and Drug Administration (FDA) in response to Spiral’s first pre-Investigational New Drug (pre-IND) package submission.

Read more: https://www.prnewswire.com/news-releases/spiral-therapeutics-receives-positive-ind-submission-guidance-from-fda-300524868.html

Close Menu